Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Craniocervical Dysfunction Index in Turkish Patients With Non-specific Neck Pain

NCT06640322 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2025-01
Last updated
2024-10-15

Condition(s) studied

Neck PainCraniocervical Disfunction

Investigational drug(s) / intervention(s)

Reliability and validity

Reliability and validity: Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Non-specific Neck Pain

Study summary

The aims of this study were to perform cultural adaptation of the Craniocervical Dysfunction Index in patients with non-specific neck pain, reliability and validity of the index Turkish speaking adults.

Eligibility

Sex
ALL
Min age
20 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Between the ages of 20-60 years * Clinical diagnosis of non-specific neck pain * Being able to communicate in Turkish * Volunteering to participate in the study Exclusion Criteria: * Over 60 years of age * Those with impairments in cervical mobility that affected the postural assessment

Primary outcome measure(s)

  • Craniocervical Dysfunction Index — Baseline
    The assessment of craniocervical dysfunction is performed objectively and comprehensively through the Craniocervical Dysfunction Index (CDI), which was developed based on the Helkimo Dysfunction Index. The CDI numerically grades the severity of the functional disorders of the cervical spine. Through this index it is possible to assess the craniocervical dysfunction, regardless of the opinion of the patients, of the severity of the symptoms, and of the need for treatment. The CDI objectively indicates the dysfunction of the cervical region by numerical average, assessing the degree of dysfunction and enabling the differential diagnosis, suggesting the priority and monitoring of the treatment these changes may be reassessed over time.

Trial sites (1)

FacilityCityRegionStatus
Alanya Alaadin Keykubat University Antalya Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06640322 on ClinicalTrials.gov ↗ ← All trials in Turkey